Advaxis, Inc. (NASDAQ:ADXS)’s shares gained 15.43% to $5.61. The company on Dec. 19 announced that it has executed definitive securities purchase agreements with two institutional investors for gross proceeds of approximately $16.7 million in a registered direct offering of approximately 3.9 million shares at a price of $4.25 per share.
Should Investors Buy ADXS After The Recent Development? Find Out Here
Adage Capital Management, L.P. (Adage) was the lead investor in this financing, with certain funds and accounts managed by T. Rowe Price Associates, Inc. also participating in the transaction. Proceeds from this financing will be used primarily to fund the continued clinical development of Advaxis’s cancer immunotherapy pipeline.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s shares increased 12.41% to $4.80. ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (XON), a leader in synthetic biology, on Dec. 3 announced the presentation of clinical and preclinical studies from their immuno-oncology programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting taking place December 1-4, 2014 in Orlando, Florida.
Is ZIOP Going To Rise or Fall After Today’s Price Action? Find Out Here
CEL-SCI Corporation (NYSEAMEX:CVM)’s stock jumped 11.24% to $0.65. The company on Dec. 8 announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). Patient screening has begun at new clinical centers in France, Turkey, Poland, Sri Lanka, Russia and Taiwan.
Can Traders Buy CVM After The Solid Rally? Get Free Trend Analysis Here
A total of 880 patients are expected to be enrolled through over 100 clinical sites in about 20 countries by the end of 2015 in the world’s largest Phase III trial for head and neck cancer.
About thenextbigtrade.com
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
Disclaimer
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
]]>
Free Urgent Insider Catalyst Report For ARIA Available Here
Gilead Sciences, Inc.(NASDAQ:GILD) shares increased 3.68% to $78.07. The company on Jan. 13 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for idelalisib, a targeted, oral inhibitor of PI3K delta, for the treatment of refractory indolent non-Hodgkin’s lymphoma (iNHL). FDA has granted a standard review for the iNHL NDA and has set a target review date under the Prescription Drug User Fee Act (PDUFA) of September 11, 2014.
Free Urgent Insider Catalyst Report For GILD Available Here
CEL-SCI Corporation (NYSEAMEX:CVM) stock dropped 5.83% to $0.88. The company on Jan. 2 reported financial results for the fiscal year ended September 30, 2013. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2013. The company reported an operating loss of ($19.87) million in fiscal year 2013 versus an operating loss of ($17.24) million in fiscal year 2012. CEL-SCI’s net loss available to common shareholders for the fiscal year 2013 was ($9.23) million, or ($0.30) per share, versus a loss of ($17.65) million, or ($0.70) per share for the fiscal year 2012.
]]>